Rxo (RXO) Total Current Liabilities (2021 - 2026)

Rxo (RXO) has reported Total Current Liabilities for 6 consecutive years, with $1.2 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 39.43% year-over-year to $1.2 billion; the trailing twelve-month figure through Jun 2026 stood at $1.2 billion (up 39.43% YoY), and the FY2025 full-year result was $1.0 billion, down 2.54% from the prior year.
• Total Current Liabilities climbed to $1.2 billion in Q2 2026 per RXO's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Total Current Liabilities topped out at $1.2 billion in Q2 2026 and bottomed at $662.0 million in Q2 2024.
• Historically, Total Current Liabilities has averaged $878.2 million across 5 years, with a median of $884.0 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities dropped 18.02% in 2023, then surged 56.16% in 2024.
• Over 5 years, Total Current Liabilities stood at $823.0 million in 2022, then retreated by 17.13% to $682.0 million in 2023, then soared by 56.16% to $1.1 billion in 2024, then retreated by 2.54% to $1.0 billion in 2025, then advanced by 18.21% to $1.2 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $1.2 billion, $1.0 billion, and $1.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.